Equities

Hexima Ltd

HXL:ASX

Hexima Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.011
  • Today's Change0.00 / 0.00%
  • Shares traded8.13k
  • 1 Year change0.00%
  • Beta0.6970
Data delayed at least 20 minutes, as of May 21 2024 06:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hexima Limited is an Australia-based company. The Company is exploring opportunities for transactions with third parties which could enable the potential value of the Company’s assets, including its intellectual property and other intangible assets, to be realized.

  • Revenue in AUD (TTM)193.85k
  • Net income in AUD-753.18k
  • Incorporated1997
  • Employees--
  • Location
    Hexima LtdLa Trobe Institute for Molecular ScienceLevel 4, LIMS2, La Trobe UniversityMELBOURNE 3086AustraliaAUS
  • Phone+61 39479-1210
  • Fax+61 38610-0599
  • Websitehttps://hexima.com.au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nutritional Growth Solutions Ltd4.48m-4.34m1.00m--------0.2245-0.0239-0.02390.0232-0.00111.512.1961.53---145.93---303.09--28.2242.47-96.95-152.300.1888--1.96--1.2641.6131.91------
Melodiol Global Health Ltd19.60m-35.52m1.43m--------0.0728-0.2548-0.37620.1578-0.01720.68744.3510.62---124.57-102.92-387.77-152.3215.38---181.22-348.920.1594-6.711.73--210.1394.60-62.47---46.82--
Wellfully Ltd1.31m-1.34m1.48m36.00------1.13-0.003-0.0030.0034-0.00340.3770.31661.57---38.36-175.88---441.8448.61---101.74-266.080.2159-------42.78-5.8712.98--21.75--
Hexima Ltd193.85k-753.18k1.84m----0.7221--9.48-0.0045-0.00450.00120.01520.0558--0.2705---21.67-72.85-26.54-193.37-----388.54-213.09----0.00--271.52-19.4380.85------
Tryptamine Therapeutics Ltd1.21m-4.32m1.93m----1.78--1.60-0.0162-0.01620.00370.00620.2368-------84.69-66.34-120.26-79.70-----357.70-228.11---21.620.00---18.97138.7329.29--68.45--
BPH Global Ltd0.00-2.56m1.95m31.00---------0.002-0.00250.00-0.00020.000.00-----177.78-68.17-784.87-128.99--15.29---131.890.5587-4.92-----99.93-74.0819.71--1.34--
Holista Colltech Limited5.95m-4.81m2.79m3.00------0.4686-0.0172-0.01720.0213-0.00711.352.494.70---111.49-42.59-347.69-63.5856.6656.37-82.68-39.270.2845-------27.82-5.65-230.77---37.12--
Hydration Pharmaceuticals Co Ltd15.06m-12.15m3.96m--------0.2632-0.0623-0.06230.0772-0.0021.181.616.60---94.86-79.98-143.75-111.5753.7048.73-80.69-99.531.37-21.481.10--10.3419.2723.61------
Bod Science Ltd3.32m-7.95m4.26m--------1.28-0.0557-0.05570.0235-0.00460.75332.428.05---180.40-94.62-465.66-145.7769.2347.08-239.47-129.480.8319--3.71---34.7023.20-47.10--8.23--
Cambium Bio Ltd-28.22k-366.01k5.36m-----------0.0012-0.0012-0.00009-0.0036-0.039-------50.58-49.44---292.47-------118.34------------60.86------
Zelira Therapeutics Ltd1.62m-36.43m5.45m8.00------3.36-3.23-3.230.148-0.20630.08480.1853.55---193.14-27.71-243.04-28.8182.28---2,278.17-508.480.1488-22.80-----80.95-0.363553.35------
Data as of May 21 2024. Currency figures normalised to Hexima Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.